CR7023A - Compuestos utiles contra enfermedades desmielinizantes como la esclerosis multiple - Google Patents
Compuestos utiles contra enfermedades desmielinizantes como la esclerosis multipleInfo
- Publication number
- CR7023A CR7023A CR7023A CR7023A CR7023A CR 7023 A CR7023 A CR 7023A CR 7023 A CR7023 A CR 7023A CR 7023 A CR7023 A CR 7023A CR 7023 A CR7023 A CR 7023A
- Authority
- CR
- Costa Rica
- Prior art keywords
- diseases
- multiple sclerosis
- demelinizing
- treatment
- useful compounds
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 101000911753 Homo sapiens Protein FAM107B Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 102100026983 Protein FAM107B Human genes 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
EL N-(PIRIDINIL)-1H-INDOL-1-AMINA DE LA FORMULA 1 PROPORCIONA UNA COMBINACION UNICA DE PROPIEDADES BLOQUEADORAS PARA AMBOS CANALES DE POTASIO Y DE SODIO. ESTOS COMPONENTES UTILES PARA EL TRATAMIENTO DE LAS ENFERMEDADES Y CONDICIONES DE DESMIELINIZACION COMO LA ESCLEROSIS MULTIPLE, LESIONES EN LA MEDULA ESPINAL, LESIONES CEREBRALES TRAUMATICAS Y GOLPES. ESTOS COMPONENTES SON UTILES TAMBIEN PARA LA REHABILITACION POR GOLPES, EL TRATAMIENTO DE INFLAMACION DE LA VEJIGA Y DISFUNCIONES, EL TRATAMIENTO DE DOLORES NEUROPATICOS Y DOLORES INDUCIDOS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26884601P | 2001-02-15 | 2001-02-15 | |
| GBGB0119435.6A GB0119435D0 (en) | 2001-02-15 | 2001-08-09 | Method of treating of demyelinating diseases or conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR7023A true CR7023A (es) | 2003-11-17 |
Family
ID=23024747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR7023A CR7023A (es) | 2001-02-15 | 2003-07-16 | Compuestos utiles contra enfermedades desmielinizantes como la esclerosis multiple |
Country Status (39)
| Country | Link |
|---|---|
| US (10) | US6967210B2 (es) |
| EP (1) | EP1368031A2 (es) |
| JP (3) | JP2004518711A (es) |
| KR (3) | KR100951540B1 (es) |
| CN (2) | CN1529598A (es) |
| AP (1) | AP1749A (es) |
| AR (1) | AR035750A1 (es) |
| AU (3) | AU2002247200B9 (es) |
| BR (1) | BR0207272A (es) |
| CA (1) | CA2438712A1 (es) |
| CO (1) | CO5390085A1 (es) |
| CR (1) | CR7023A (es) |
| CZ (1) | CZ20032172A3 (es) |
| EA (2) | EA012409B1 (es) |
| EC (1) | ECSP024218A (es) |
| EE (1) | EE200300363A (es) |
| GB (1) | GB0119435D0 (es) |
| HK (1) | HK1080361B (es) |
| HR (1) | HRP20030652A2 (es) |
| HU (1) | HUP0303203A3 (es) |
| IL (2) | IL157341A0 (es) |
| MA (1) | MA26152A1 (es) |
| ME (1) | MEP21208A (es) |
| MX (1) | MXPA03006110A (es) |
| MY (1) | MY157745A (es) |
| NO (1) | NO20033622L (es) |
| NZ (4) | NZ544720A (es) |
| OA (1) | OA12549A (es) |
| PA (1) | PA8540101A1 (es) |
| PE (1) | PE20040175A1 (es) |
| PL (1) | PL363638A1 (es) |
| SG (1) | SG134170A1 (es) |
| SK (1) | SK10392003A3 (es) |
| TR (4) | TR200800693T2 (es) |
| TW (1) | TWI325319B (es) |
| UA (2) | UA80394C2 (es) |
| WO (1) | WO2002064126A2 (es) |
| YU (1) | YU62903A (es) |
| ZA (1) | ZA200306124B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
| ES2288641T3 (es) * | 2002-12-20 | 2008-01-16 | Dynogen Pharmaceuticals Inc. | Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta. |
| AU2004207010A1 (en) * | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using sodium channel modulators |
| EP1721607A1 (en) * | 2003-03-21 | 2006-11-15 | Dynogen Pharmaceuticals, Inc. | Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| GT200500063A (es) * | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
| GB0510164D0 (en) * | 2005-04-28 | 2005-06-22 | Paradigm Therapeutics Ltd | Ion channel |
| FR2892021B1 (fr) * | 2005-10-19 | 2008-01-04 | Urogene | Traitement de l'incontinence urinaire d'effort et mixte |
| FR2892022B1 (fr) * | 2005-10-19 | 2008-01-04 | Urogene Sa | Traitement des symptomes de l'irritation de la vessie |
| US8420593B1 (en) * | 2006-06-16 | 2013-04-16 | Landon C. G. Miller | Compositions and methods for regulating membrane potential |
| DE102008044844B4 (de) * | 2008-08-28 | 2018-08-30 | Siemens Healthcare Gmbh | Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes |
| KR101862539B1 (ko) * | 2010-03-26 | 2018-05-31 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 반도체 장치 |
| WO2012009204A1 (en) * | 2010-07-15 | 2012-01-19 | The Trustees Of Columbia University In The City Of New York | Methods for diagnosing and treating concussive disorders |
| US20130030025A1 (en) * | 2011-01-28 | 2013-01-31 | Wessel Thomas C | Use of potassium channel blockers to treat cerebral palsy |
| TWI592156B (zh) * | 2011-10-04 | 2017-07-21 | 艾可達醫療公司 | 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| WO2019126643A1 (en) * | 2017-12-22 | 2019-06-27 | Massachusetts Institute Of Technology | Compositions and methods for williams syndrome (ws) therapy |
| WO2022159086A1 (en) * | 2021-01-20 | 2022-07-28 | Rush University Medical Center | Improved treatment for globoid cell leukodsytrophy or krabbe disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE115143T1 (de) * | 1987-04-24 | 1994-12-15 | Hoechst Roussel Pharma | N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel. |
| US4970218A (en) * | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| FI95466C (fi) | 1989-08-02 | 1996-02-12 | Hoechst Roussel Pharma | Menetelmä terapeuttisesti aktiivisten 2,3-dihydro-1-(pyridyyliamino)indolien valmistamiseksi |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| DE4325491A1 (de) * | 1993-07-29 | 1995-02-02 | Boehringer Ingelheim Kg | Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels |
| US5459274A (en) | 1994-05-13 | 1995-10-17 | Hoechst-Roussel Pharmaceuticals Inc. | Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines |
| US5565475A (en) | 1994-11-08 | 1996-10-15 | Muhlhauser; Mark A. | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives |
| EP0731108A1 (en) | 1995-03-10 | 1996-09-11 | Boehringer Mannheim Gmbh | Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes |
| FR2754147B1 (fr) | 1996-10-03 | 2000-02-04 | Mbh Technologies Sa | Installation et procede pour le traitement de carcasses |
| DK1056754T3 (da) * | 1998-01-29 | 2004-02-16 | Bristol Myers Squibb Co | Phosphatderivater af diaryl-1,3,4-oxadiazolon |
| AU5483500A (en) | 1999-07-09 | 2001-01-30 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2001
- 2001-08-09 GB GBGB0119435.6A patent/GB0119435D0/en not_active Ceased
-
2002
- 2002-02-14 MX MXPA03006110A patent/MXPA03006110A/es active IP Right Grant
- 2002-02-14 CN CNA028048644A patent/CN1529598A/zh active Pending
- 2002-02-14 HR HR20030652A patent/HRP20030652A2/hr not_active Application Discontinuation
- 2002-02-14 EA EA200600896A patent/EA012409B1/ru not_active IP Right Cessation
- 2002-02-14 TR TR2008/00693T patent/TR200800693T2/xx unknown
- 2002-02-14 TR TR2008/00692T patent/TR200800692T2/xx unknown
- 2002-02-14 CA CA002438712A patent/CA2438712A1/en not_active Abandoned
- 2002-02-14 EE EEP200300363A patent/EE200300363A/xx unknown
- 2002-02-14 NZ NZ544720A patent/NZ544720A/en unknown
- 2002-02-14 AP APAP/P/2003/002834A patent/AP1749A/en active
- 2002-02-14 HU HU0303203A patent/HUP0303203A3/hu unknown
- 2002-02-14 NZ NZ539159A patent/NZ539159A/en unknown
- 2002-02-14 SK SK1039-2003A patent/SK10392003A3/sk unknown
- 2002-02-14 TR TR2008/00691T patent/TR200800691T2/xx unknown
- 2002-02-14 BR BR0207272-6A patent/BR0207272A/pt not_active IP Right Cessation
- 2002-02-14 NZ NZ556697A patent/NZ556697A/en unknown
- 2002-02-14 TR TR2003/01330T patent/TR200301330T2/xx unknown
- 2002-02-14 JP JP2002563920A patent/JP2004518711A/ja not_active Ceased
- 2002-02-14 EA EA200300882A patent/EA011319B1/ru not_active IP Right Cessation
- 2002-02-14 US US10/076,191 patent/US6967210B2/en not_active Expired - Lifetime
- 2002-02-14 KR KR1020037010691A patent/KR100951540B1/ko not_active Expired - Fee Related
- 2002-02-14 PL PL02363638A patent/PL363638A1/xx not_active Application Discontinuation
- 2002-02-14 ME MEP-212/08A patent/MEP21208A/xx unknown
- 2002-02-14 AU AU2002247200A patent/AU2002247200B9/en not_active Ceased
- 2002-02-14 CN CNB2005100597348A patent/CN100522164C/zh not_active Expired - Fee Related
- 2002-02-14 WO PCT/US2002/005501 patent/WO2002064126A2/en not_active Ceased
- 2002-02-14 KR KR1020087031855A patent/KR100951542B1/ko not_active Expired - Fee Related
- 2002-02-14 EP EP02714974A patent/EP1368031A2/en not_active Withdrawn
- 2002-02-14 UA UA2003098376A patent/UA80394C2/uk unknown
- 2002-02-14 CZ CZ20032172A patent/CZ20032172A3/cs unknown
- 2002-02-14 KR KR1020087031854A patent/KR20090005254A/ko not_active Ceased
- 2002-02-14 NZ NZ527011A patent/NZ527011A/en unknown
- 2002-02-14 YU YU62903A patent/YU62903A/sh unknown
- 2002-02-14 IL IL15734102A patent/IL157341A0/xx unknown
- 2002-02-14 OA OA1200300199A patent/OA12549A/en unknown
- 2002-02-14 SG SG200505802-9A patent/SG134170A1/en unknown
- 2002-02-15 CO CO02013025A patent/CO5390085A1/es not_active Application Discontinuation
- 2002-02-15 AR ARP020100540A patent/AR035750A1/es unknown
- 2002-02-15 EC EC2002004218A patent/ECSP024218A/es unknown
- 2002-02-15 MY MYPI20020518A patent/MY157745A/en unknown
- 2002-02-15 TW TW091102861A patent/TWI325319B/zh not_active IP Right Cessation
- 2002-02-18 PA PA20028540101A patent/PA8540101A1/es unknown
- 2002-02-26 PE PE2002000159A patent/PE20040175A1/es not_active Application Discontinuation
-
2003
- 2003-07-11 MA MA27235A patent/MA26152A1/fr unknown
- 2003-07-16 CR CR7023A patent/CR7023A/es unknown
- 2003-08-07 ZA ZA200306124A patent/ZA200306124B/xx unknown
- 2003-08-11 IL IL157341A patent/IL157341A/en not_active IP Right Cessation
- 2003-08-14 NO NO20033622A patent/NO20033622L/no not_active Application Discontinuation
-
2004
- 2004-02-03 US US10/770,656 patent/US20040157889A1/en not_active Abandoned
- 2004-02-03 US US10/770,655 patent/US20040157888A1/en not_active Abandoned
-
2005
- 2005-03-14 US US11/079,327 patent/US7230015B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/079,366 patent/US7179821B2/en not_active Expired - Lifetime
- 2005-09-27 US US11/236,145 patent/US7534803B2/en not_active Expired - Fee Related
-
2006
- 2006-01-05 HK HK06100186.8A patent/HK1080361B/zh not_active IP Right Cessation
- 2006-04-04 UA UAA200603708A patent/UA88773C2/ru unknown
-
2008
- 2008-03-13 AU AU2008201179A patent/AU2008201179B2/en not_active Ceased
-
2009
- 2009-04-06 JP JP2009091807A patent/JP2009185045A/ja not_active Abandoned
- 2009-04-29 US US12/420,390 patent/US20090281147A1/en not_active Abandoned
- 2009-04-29 US US12/420,416 patent/US20090209595A1/en not_active Abandoned
- 2009-04-29 US US12/420,407 patent/US20090209594A1/en not_active Abandoned
- 2009-04-29 US US12/420,381 patent/US20090270458A1/en not_active Abandoned
- 2009-11-19 AU AU2009238332A patent/AU2009238332A1/en not_active Abandoned
-
2010
- 2010-02-16 JP JP2010030929A patent/JP2010120958A/ja not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR7023A (es) | Compuestos utiles contra enfermedades desmielinizantes como la esclerosis multiple | |
| CY1108808T1 (el) | Ενωσεις μοτιλιδης | |
| BRPI0415167A (pt) | composto de amina como ligandos de canal de ìon e usos dos mesmos | |
| BRPI0408026A (pt) | Quinazolinas úteis como moduladores de canais de ìon | |
| PA8571001A1 (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
| MY135333A (en) | Modulators of the glucocorticoid receptor | |
| BRPI0418181A (pt) | emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| EE200300559A (et) | Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks | |
| CR7195A (es) | Nuevos derivados de oxazolidinonas como antibacterianos | |
| BRPI0417858A (pt) | composto, composição farmacêutica, e, uso de uma composição farmacêutica | |
| BR0308133A (pt) | Forma polimórfica cristalina de cloridrato de irinotecan | |
| HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
| AR029428A1 (es) | DERIVADOS DE FENIL--PIPERIDINA, TETRAHIDROPIRIDINA,-PIPERAZINA,-AZEPAN,-TETRAHIDRO-1H-AZEPINA Y DIAZEPAN SUSTITUIDOS, UNA COMPOSICIoN FARMACEUTICA Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UNA PREPARACION FARMACEUTICA | |
| CY1107158T1 (el) | Νεα παραγωγα της ισοκινολινης, η μεθοδος παρασκευης τους και η χρηση τους για τη θεραπεια των διαταραχων του μελατονινεργικου συστηματος | |
| ECSP044971A (es) | Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson | |
| PL372769A1 (en) | Cyanoguanidine prodrugs | |
| ATE373644T1 (de) | N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika | |
| BRPI0408077A (pt) | composições e métodos para prevenção e tratamento de doenças relacionadas com endotoxina e condições | |
| ITBO20030261A1 (it) | Unita'di irraggiamento luminoso per diagnosi e cura di problemi cutanei. | |
| EA200501259A1 (ru) | Комбинированное применение фибрата и орлистата для лечения ожирения | |
| PA8558901A1 (es) | Nuevos compuestos hexaciclicos | |
| UY27206A1 (es) | Método de tratamiento de condiciones o enfermedades desmielinizantes | |
| GT200000114A (es) | Forma cristalina iii de la n-(4-(5-dimetilaminoftalen-1-sulfonilamino) fenil)-3-hidroxi-2, 2-dimetilpropionamida. | |
| NO20053562L (no) | Nye aminobenzofenonforbindelser |